FDA Plugs HDE Program, Shows Flexibility With Population, Cost Criteria
This article was originally published in The Gray Sheet
Executive Summary
FDA is seeking broader use of the humanitarian device exemption program by encouraging dialogue with manufacturers about HDE requirements for patient population and cost
You may also be interested in...
DePuy Weighs HDE Costs; FDA Stresses Data Options Over Statutory Limits
The Center for Devices & Radiological Health is encouraging greater use of humanitarian device exemptions by inviting manufacturers to submit alternative forms of data to support submissions
Investors Go Beserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continue, while companies with governance doubts see shareholders retreat.